硼替佐米对多发性骨髓瘤CLC-3表达的影响

摘要

目的：：研究接受硼替佐米化疗的多发性骨髓瘤( MM)患者在化疗前后CLC-3蛋白表达的变化,探讨硼替佐米对MM患者CLC-3的影响及疗效的变化。方法：流式细胞技术分离12例初发、及复发难治的多发性骨髓瘤患者的浆(瘤)细胞,检测其CLC-3蛋白表达情况。然后所有观察病例均予以硼替佐米为主的化疗方案治疗至少4(4-6)个疗程,检测其CLC-3蛋白表达的水平,了解该指标与临床疗效的关系。结果：12例MM患者治疗前的CLC-3均存在高表达。经硼替佐米为主的化疗方案治疗后,其表达水平呈下降趋势。6例完全缓解( CR)及4例非常好的部分缓解( VGPR)的患者,CLC-3表达水平恢复接近正常。结论：硼替佐米可以对多发性骨髓瘤患者的CLC-3的表达情况产生影响,CLC-3表达水平与硼替佐米疗效呈负相关性。硼替佐米直接能否下调CLC-3水平,以及氯通道可否作为治疗该病的新靶点值得进一步研究。%Objective:To explore expression of CLC-3 level on bortezomib combined regimen in treatment of mul-tiple myeloma ( MM) . Methods:Twelve newly diagnosed and relapsed / refractory MM treated with the regimen of combination of bortezomib and dexamethasone in a cycle of 4 weeks,at least 4 (4-6)courses. Results:Total response rate was 100%(12/12),and the rate of CR + VGPR was 83%(10/12) after treated with bortezomib. Expression of CLC-3 level in MM ( CR+VGPR) returned to normal. Conclusion:The Bortezomib combined regimen has significant effect in MM treatment and maybe reduce expression of CLC-3 level.